Earnings Inflated by Asset Sale; Adjusted Growth Strong but Margins Compress
Reported PAT jumped 115% to ₹74.4 Cr, but ₹24.1 Cr is a one-time facility sale gain. The adjusted reality—₹50.3 Cr, +45% organic—reveals the real tension: strong operational outperformance offset by 100-basis-point margin compression and pricing-pass-through lags that management hasn't yet conquered.
₹74.4 Cr
+115% YoY
₹24.1 Cr
32.5% of PAT
₹50.3 Cr
+45.2% YoY (organic)
30%
−100 bps QoQ; guided 27–28%
S.J.S. Enterprises delivered record revenue of ₹261 Cr and reported PAT growth of 115%, but this quarter's earnings carry a critical asterisk. ₹24.1 Cr of the ₹74.4 Cr PAT comes from the sale of an unused Bangalore facility—a one-time, non-operational gain. Strip it out and the adjusted PAT is ₹50.3 Cr, up 45.2% organically. That's a healthy beat, but it masks a deeper problem: EBITDA margin compressed 100 basis points quarter-on-quarter to 30%, despite management claims of pricing power, and sits 200–300 basis points above the guided 27–28% long-term target. The gap is input-cost headwinds (50–60 bps) that pricing hasn't yet fully recovered.
Where the profit came from
Highest-ever quarterly revenue and profitability since listing.
₹261 Cr revenue confirmed; ₹74.4 Cr PAT is record headline, but ₹24.1 Cr is one-time facility sale—adjusted operating PAT ₹50.3 Cr is strong but not a step-change from prior quarters.
Overstated (headlines mislead)
115% YoY PAT growth with strong operational performance.
Headline growth inflated by one-time gain; adjusted PAT +45.2% YoY on solid auto outperformance (+32.4% vs. 21.7% industry).
Contradicted (adjusted reality)
EBITDA margin improved to 30% on product mix and export contribution.
30% EBITDA margin down 100 bps QoQ from 31%; margin compression despite pricing claims. Gross margin up only 10 bps (56.7% vs 56.6% QoQ); input cost headwind of 50–60 bps only partially offset.
Contradicted (margin declined)
Pricing already being passed to customers; gross margin stable.
Q4 gross margin 56.6% vs Q1 56.7%—10 bps improvement only. Pricing pass-through acknowledged as lagged 1–2 quarters; recovery only partial this quarter.
Partial (lag persists)
SJS outperforming industry by 1.5x (32.4% auto growth vs. 21.7% industry).
32.4% SJS auto growth vs. combined 21.7% PV + 2W industry growth confirmed. 27 consecutive quarters of outperformance tracked.
Supported (strong track record)
What changed on this call
Guidance reaffirmed, not raised. 27–28% EBITDA margin held despite 100 bps QoQ compression; timing to recover now pushed toward new product ramps (BOE, Decoplast).
Decoplast Pune facility commissioned Aug 2026 on schedule; adds ₹200–250 Cr revenue capacity over 3 years. Breakeven expected at 1–1.25x asset turn (likely near end of FY27 or Q1 FY28). Order book described as 'very strong.'
BOE cover glass & display facility on track for Q2 FY28 production start. Development samples now at OEM customers (Tier-1 suppliers and OEMs) for testing. Margin profile TBD post-PPAP validation.
Export growth accelerating: 9.8% of revenue, +83% YoY. Target 14–15% by FY28 held firm; 'large businesses under discussion' but no firm customer orders disclosed.
Walter Pack India new business (tooling delayed 2+ quarters) still under development; Mahindra confirmed as customer. Management non-committal on timing or magnitude.
The bull-bear ledger
27 consecutive quarters of automotive industry outperformance (1.5x multiple); organic PAT growth of +45.2% shows pricing power and cost discipline in core business.
Strong balance sheet: ₹3,287.7 Cr net cash; ROCE 37.2%, ROE 20.3%, free cash flow ₹838 Cr this quarter (101% of EBITDA). Capacity to invest and return capital.
Multiple growth levers in pipeline: BOE display (Q2 FY28 ramp, ₹5,000–7,000 Cr India TAM by 2030), Decoplast (₹200–250 Cr 3-year revenue add), export acceleration (target 14–15% by FY28), new product mix (24% of revenue now).
32% of Q1 PAT is a one-time facility sale gain, not operational. Reported growth headline masks organic reality: adjusted +45% is solid, but not the +115% the street initially reads.
EBITDA margin down 100 bps QoQ to 30%, and 200–300 bps above guided 27–28% long-term. Pricing pass-through lagged 1–2 quarters; only 10 bps of gross margin improvement despite claims of 'significant' pricing recovery. 50–60 bps input cost headwind still embedded.
New products (BOE display, Decoplast, Walter Pack new business) are execution-dependent, with no firm customer orders disclosed and timelines that have already slipped (Walter Pack tooling delayed 2+ quarters). Margin profile for BOE TBD.
Automotive industry growth assumption of 21.7% YoY this quarter validates 1.5x–2x outperformance guidance, but macro softness could erode baseline; SJS outperformance is dependent on industry growing 20%+.
Risks ranked by concern for a holder
EBITDA margin compression. 30% now vs. 27–28% guided; 100 bps QoQ decline despite pricing claims.
HighIf input cost recovery stalls and pricing pass-through remains lagged 1–2 quarters, guided margins fall out of reach. Earnings power is at risk if margins don't recover by Q2/Q3. Street likely reprices lower if guidance is revised down.
BOE display facility execution and timing. No customer orders disclosed; only development samples at OEMs. Margin profile TBD until manufacturing begins.
MediumRevenue recognition could slip beyond Q2 FY28 if PPAP validation delays or customer approvals stall. Margin upside is unproven; if manufacturing costs exceed expectations, new business margin could disappoint.
Decoplast capacity utilization. 3-year ramp to 85–90% utilization with ₹200–250 Cr revenue target contingent on export orders materializing.
MediumIf orders don't flow as expected, underutilization would drag ROCE and free cash flow. Order book cited as 'very strong' but not detailed.
Automotive industry growth slowdown. Q1 baseline was +21.7%; if macro cools, industry drops below 15–18% growth, SJS 1.5x–2x outperformance assumption becomes harder to sustain.
MediumValuation and growth guidance are anchored to automotive industry assumptions. Softness could cascade into SJS guidance revisions.
Walter Pack new business delays. 'Under discussion' for 2+ quarters; tooling timelines repeatedly pushed. No firm customer wins disclosed beyond Mahindra.
LowTiming uncertainty but not demand constraint; Walter Pack has 25% spare capacity. More of an execution question than a structural risk.
How the street is positioned
The stock opened to a muted +0.34% pop on day 1 after results, suggesting the market had already priced in strong auto outperformance. Price is now ₹2,372, down 8.4% from its all-time high of ₹2,589.6, but still +60.89% off the 52-week low and trading well above all key moving averages (SMA20 ₹2,324.56, SMA50 ₹2,216.54, SMA200 ₹1,851.39). RSI at 60.7 sits in neutral-to-overbought territory. Volume trend is increasing, suggesting institutional interest remains.
Ownership flows are sending mixed signals. DIIs accumulated +2.95 percentage points (31.09% → 34.04%), the largest quarterly inflow in the last year, and are now the single largest holder. FIIs, by contrast, trimmed −1.01 percentage points (15.68% → 14.67%)—a reversal after stable ownership through FY26 Q2–Q4. Promoters also reduced stake by −1.00pp (21.15% → 20.15%). The divergence matters: DIIs buying into margin pressure and one-time-gain headwinds suggests confidence in long-term positioning; FII exits in a muted post-result environment could reflect concern about near-term margin recovery or valuation at current levels.
1 · Q2 FY27 organic PAT and gross margin
Can pricing pass-through move faster than the lagged 1–2 quarters management cited? If gross margin stays flat and EBITDA margin re-compresses, the 27–28% guided range is in jeopardy. The adjusted PAT (ex one-time items) should be tracked, not the headline.
2 · BOE display revenue recognition and margin
Does Q2 FY28 production start materialize? Any customer order announcements? Margin profile should be disclosed before revenue recognition begins. This is the single largest unproven lever in guidance.
3 · Decoplast order flow and utilization trajectory
Over Q2–Q4 FY27, watch for new customer wins disclosed and capacity utilization commentary. If orders don't flow, expect management to guide down on the 3-year ₹200–250 Cr revenue ramp.
S.J.S. Enterprises delivered a quarter that proved consistency, not a step-change. The 27 consecutive quarters of outperformance, +45% adjusted PAT, and ₹3.3 Cr net cash position are all genuine strengths. But earnings quality matters: the ₹24.1 Cr one-time gain inflates perception, and the 100-basis-point margin compression is a real concern. Management's pricing power is proven over decades, but the 50–60 bps input cost headwind and lagged 1–2 quarter recovery window mean margins are at risk near-term. The stock's 8.4% drawdown from ATH and flat day-1 reaction suggest the market is cautious; DIIs accumulating against FII exits is a tell. Margins and the timing of new-product revenue ramps (BOE Q2 FY28, Decoplast ramp-up over 3 years) are the two numbers to watch. Track the adjusted PAT and gross margin recovery trajectory, not the headline PAT. Guidance holds, but execution on margins is now the credibility test.
Informational and educational content only. Not investment advice.